High purity CJC-1295 and Ipamorelin are research compounds investigated for their synergistic activation of growth hormone secretagogue receptors. In preclinical models, this combination exhibits selective, pulsatile growth hormone release without driving significant elevations in secondary hormones like cortisol or prolactin.
High purity CJC-1295 and Ipamorelin are research compounds investigated for their synergistic activation of growth hormone secretagogue receptors. In preclinical models, this combination exhibits selective, pulsatile growth hormone release without driving significant elevations in secondary hormones like cortisol or prolactin.
In biomedical literature, the co-administration of modified growth hormone-releasing hormone (GHRH) analogues alongside selective ghrelin receptor agonists represents a well-characterized approach to studying somatotroph signaling. Obtaining high purity CJC-1295 and Ipamorelin is essential for cellular and animal models where trace peptide impurities, residual trifluoroacetic acid (TFA), or bacterial endotoxins could confound experimental end points.
When purchasing compounds for laboratory research use only, investigators require defined purity thresholds validated by liquid chromatography-mass spectrometry (LC-MS) and reverse-phase high-performance liquid chromatography (RP-HPLC). High-purity formulations ensure that receptor binding kinetics, signal transduction cascades, and secretagogue potency remain reproducible across different assay batches. Researchers can explore our complete catalog of research peptides for analytical-grade reagents engineered for demanding experimental protocols.
The combination of CJC-1295 and Ipamorelin leverages two distinct, complementary signaling pathways within the anterior pituitary gland. CJC-1295 functions as a synthetic 29-amino-acid peptide analogue of natural GHRH, binding to the GHRH receptor (GHRHR) to stimulate adenylate cyclase and increase intracellular cyclic adenosine monophosphate (cAMP) levels.
Conversely, Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Activation of GHS-R1a triggers intracellular calcium mobilization via the phospholipase C (PLC) pathway. Preclinical studies suggest that simultaneously targeting both GHRHR and GHS-R1a produces a synergistic release of endogenous growth hormone (GH) far greater than the additive effect of either secretagogue administered independently. To study individual secretagogues, researchers often utilize CJC-1295 No DAC or standalone ghrelin mimetics.
Natural growth hormone secretion is characteristically pulsatile, oscillating according to circadian rhythms and hypothalamic regulatory signals. Synthetic secretagogues are frequently evaluated on their ability to preserve or mimic this natural physiological waveform rather than inducing sustained, non-physiologically elevated hormone levels that may lead to down-regulation of somatotroph receptors.
In vitro assays using rodent pituitary cell cultures indicate that Ipamorelin triggers a sharp, transient pulse of GH secretion that rapidly returns to baseline. When paired with CJC-1295—which extends the half-life and signaling window at the GHRH receptor—the combination promotes elevated peak amplitudes while maintaining discrete pulsatile patterns. Animal models demonstrate that this preserved pulsatility helps prevent premature receptor desensitization and preserves feedback sensitivity within the hypothalamic-pituitary-somatotropic axis. For broader context on hormone axes, review our research library hub.
A primary challenge with early-generation growth hormone secretagogues, such as GHRP-2 and GHRP-6, was their non-selective activation of broader neuroendocrine pathways. First-generation GHRPs frequently triggered off-target elevations of adrenocorticotropic hormone (ACTH), leading to increases in serum cortisol, as well as stimulating prolactin secretion from lactotrophs.
Preclinical data indicate that Ipamorelin exhibits exceptional receptor selectivity for GHS-R1a over related neuroendocrine receptors. In canine and rodent models, administration of high purity CJC-1295 and Ipamorelin stimulated robust GH release while keeping circulating cortisol and prolactin concentrations virtually indistinguishable from baseline controls. This high degree of selectivity renders the CJC-1295/Ipamorelin combination an ideal candidate for researchers investigating pure somatotroph activation without confounding stress-hormone or lactogenic variables.
Evaluating secretagogue candidates requires understanding the functional differences across GHRH derivatives and ghrelin receptor mimetics. While CJC-1295 and Ipamorelin offer a balanced, highly selective profile, alternative constructs present distinct kinetic and receptor-binding characteristics that suit different experimental designs.
For instance, comparing CJC-1295 No DAC against Sermorelin reveals differences in plasma half-life and terminal clearance rates, whereas pairing secretagogues with GHRP-6 introduces additional ghrelin-mediated metabolic signaling pathways. The table below summarizes key preclinical differences among common secretagogue research compounds:
To guarantee experimental consistency, high purity CJC-1295 and Ipamorelin must undergo rigorous physical and chemical characterization prior to laboratory use. PX1 Research subjects every batch to comprehensive analytical evaluation, ensuring that researchers receive compounds free from synthesis side-products, truncated sequences, or residual cleavage reagents.
Purity is quantified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), where peak area integration must verify a purity level of >=98%. Simultaneously, Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) is conducted to confirm exact molecular weight and sequence identity against theoretical parameters. Detailed lot-specific documentation is available on our page covering analytical lab testing standards.
In cell culture models and preclinical animal studies, lipopolysaccharides (endotoxins) derived from Gram-negative bacterial outer membranes represent a significant source of artifactual data. Endotoxin contamination can trigger inflammatory cytokine cascades, alter cellular viability, and skew metabolic assays, masking the true physiological effects of the peptide being studied.
PX1 Research enforces strict bioburden controls across all manufacturing processes. Every lot of high purity CJC-1295 and Ipamorelin undergoes Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels fall well below established research thresholds (<0.01 EU/mg). This level of quality control ensures that observed biological responses are solely attributable to peptide-receptor interactions rather than immune stimulation.
Lyophilized CJC-1295 and Ipamorelin peptides require proper handling and reconstitution procedures to preserve structural integrity and prevent degradation. Lyophilized cakes should be allowed to equilibrate to room temperature before reconstitution to avoid condensation inside the vial.
For working laboratory solutions, reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the downstream assay. The reconstituting solvent should be directed gently against the inner glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl mixing—avoiding vigorous agitation or vortexing—is recommended to prevent mechanical shearing of the peptide backbone. Once reconstituted, stock solutions should be aliquot-sampled to avoid repeated freeze-thaw cycles and maintained at 2°C to 8°C for short-term use, or frozen at -20°C to -80°C for long-term storage.
Selecting a trustworthy supplier for research peptides requires inspecting manufacturing standards, facility compliance, and quality assurance protocols. Academic laboratories, biotechnology firms, and institutional research facilities require fully transparent sourcing to ensure compliance with institutional oversight standards.
PX1 Research synthesizes all compounds in US-based, GMP-compliant facilities. Every lot is independently audited by ISO 17025 accredited third-party laboratories to verify purity, identity, and safety metrics. Institutional buyers seeking bulk procurement or customized analytical reporting can access dedicated support through our wholesale research peptide orders division.
What is the primary mechanism of high purity CJC-1295 and Ipamorelin when combined?
The combination acts synergistically on anterior pituitary somatotrophs. CJC-1295 activates the GHRH receptor to stimulate cAMP production, while Ipamorelin selectively activates the GHS-R1a (ghrelin) receptor to mobilize intracellular calcium. Together, they promote selective, pulsatile growth hormone release.
How does Ipamorelin differ from earlier secretagogues like GHRP-2 or GHRP-6?
In preclinical models, Ipamorelin demonstrates significantly higher receptor selectivity. Unlike GHRP-2 and GHRP-6, Ipamorelin stimulates GH release without causing significant elevations in circulating ACTH, cortisol, or prolactin.
How is the purity of CJC-1295 and Ipamorelin verified?
Purity is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure a baseline purity of >=98%. Molecular structure and sequence mass are confirmed using Mass Spectrometry (ESI-MS or MALDI-TOF).
What are the recommended endotoxin limits for peptide research assays?
To avoid triggering unwanted inflammatory responses in cell culture or animal models, research-grade peptides should feature endotoxin levels below 0.05 EU/mg, with premium preparations maintaining levels under 0.01 EU/mg as tested by LAL assay.
How should lyophilized CJC-1295 and Ipamorelin be stored upon receipt?
Lyophilized vials should be stored at -20°C for short-to-medium term storage, or -80°C for long-term stability. Vials should be kept in a desiccated environment protected from direct light exposure.
What solvent is recommended for reconstituting CJC-1295 / Ipamorelin research vials?
Reconstitution is typically carried out using sterile bacteriostatic water containing 0.9% benzyl alcohol for multi-use laboratory procedures, or sterile phosphate-buffered saline (PBS) for immediate cell culture applications.
Where are PX1 Research peptides manufactured and tested?
All PX1 Research peptides are manufactured in USA-based GMP-compliant facilities and undergo independent lot testing at ISO 17025 accredited analytical laboratories.
Are CJC-1295 and Ipamorelin approved for human therapeutic use?
No. CJC-1295 and Ipamorelin are sold strictly as research chemical compounds for laboratory in vitro and preclinical in vivo research. They are not intended for medical, human, or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.